Cure My Disease

Don't miss your cure!

 Log in / Sign up

New smart drug takes aim at Hard-to-Treat blood cancers

NCT ID NCT07220616

Recruiting now Disease control Sponsor: Daiichi Sankyo Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jul 10, 2026 · Updated 2 times

Summary

This trial tests a new drug called DS3790a for people with certain blood cancers, including B-cell non-Hodgkin lymphoma. The drug is designed to find and attack cancer cells while sparing healthy ones. The study will check safety and how well it works in about 420 adults.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance
DS3790a (an antibody-drug conjugate targeting CD37, combined with a chemotherapy-like payload)
What this could lead to
If successful, this could provide a new treatment option for people with certain blood cancers that are hard to treat.
What could go wrong
This is an early (phase 1/2) trial, so the drug may not work or could cause serious side effects. It is not a cure and long-term benefits are unknown.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for B-CELL NON-HODGKIN LYMPHOMA are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

B-cell neoplasm B-cell non-Hodgkin lymphoma hematopoietic and lymphoid cell neoplasm hematopoietic and lymphoid system neoplasm

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

B-CELL NON-HODGKIN LYMPHOMA HEMATOLOGICAL MALIGNANCIES

Contacts and locations

Study contacts

  • Contact

    Email: •••••@•••••

Locations

  • Research Site

    RECRUITING

    New York, New York, 10065, United States

  • Research Site

    RECRUITING

    Lille, 59037, France

  • Research Site

    RECRUITING

    Pierre-Bénite, 69495, France

  • Research Site

    RECRUITING

    Nagoya, 464-8681, Japan

  • Research Site

    RECRUITING

    Tokyo, 104-0045, Japan

  • Research Site

    RECRUITING

    Tokyo, 135-8550, Japan

More trials for these conditions

Other studies related to the condition(s) this trial covers.